We are live on ! Find out more
BSTC

BioSpecifics Technologies Corp.
BSTC

Delisted

BSTC was delisted on the 1st of December, 2020.

90 hedge funds and large institutions have $199M invested in BioSpecifics Technologies Corp. in 2017 Q2 according to their latest regulatory filings, with 7 funds opening new positions, 34 increasing their positions, 34 reducing their positions, and 6 closing their positions.

New
Increased
Maintained
Reduced
Closed

17% more first-time investments, than exits

New positions opened: 7 | Existing positions closed: 6

1% more funds holding

Funds holding: 8990 (+1)

0% more funds holding in top 10

Funds holding in top 10: 11 (0)

0% more repeat investments, than reductions

Existing positions increased: 34 | Existing positions reduced: 34

22% less capital invested

Capital invested by funds: $255M → $199M (-$56.2M)

Holders
90
Holders Change
+1
Holders Change %
+1.12%
% of All Funds
2.24%
Holding in Top 10
1
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
0.02%
New
7
Increased
34
Reduced
34
Closed
6
Calls
Puts
Net Calls
Net Calls Change
Name Holding Trade Value Shares
Change
Change in
Stake
SLG
51
Stanley-Laman Group
Pennsylvania
$621K -$123K -2,343 -16%
ADEF
52
Adams Diversified Equity Fund
Maryland
$619K -$126K -2,400 -16%
GCP
53
GSA Capital Partners
United Kingdom
$545K -$1.14M -21,838 -66%
AL
54
AJO LP
Pennsylvania
$501K +$530K +10,124 New
TA
55
Teachers Advisors
New York
$500K +$68.4K +1,305 +15%
California State Teachers Retirement System (CalSTRS)
56
California State Teachers Retirement System (CalSTRS)
California
$496K -$31.4K -600 -6%
EGA
57
Eagle Global Advisors
Texas
$492K
FQ
58
First Quadrant
California
$456K -$1.16M -22,233 -71%
Two Sigma Investments
59
Two Sigma Investments
New York
$451K -$343K -6,553 -42%
CI
60
Cigna Investments
Connecticut
$393K -$703K -13,422 -63%
AG
61
Algert Global
California
$392K
Bank of Montreal
62
Bank of Montreal
Ontario, Canada
$346K -$13.9K -266 -4%
UBS Group
63
UBS Group
Switzerland
$344K +$39.7K +757 +12%
SGAM
64
Smith Group Asset Management
Texas
$337K -$156K -2,972 -30%
RhumbLine Advisers
65
RhumbLine Advisers
Massachusetts
$330K +$24.4K +466 +8%
FDCDDQ
66
Federation des caisses Desjardins du Quebec
Quebec, Canada
$298K
Manulife (Manufacturers Life Insurance)
67
Manulife (Manufacturers Life Insurance)
Ontario, Canada
$244K +$21.5K +410 +9%
SG Americas Securities
68
SG Americas Securities
New York
$241K +$255K +4,859 New
MLICM
69
Metropolitan Life Insurance Company (MetLife)
New York
$223K
GC
70
Globeflex Capital
California
$214K -$1.82M -34,731 -89%
CG
71
Caprock Group
Idaho
$206K +$218K +4,155 New
Millennium Management
72
Millennium Management
New York
$205K +$217K +4,140 New
Ohio Public Employees Retirement System (OPERS)
73
Ohio Public Employees Retirement System (OPERS)
Ohio
$182K
AIG
74
American International Group
New York
$174K +$9.38K +179 +5%
US Bancorp
75
US Bancorp
Minnesota
$171K +$1.89K +36 +1%

BSTC Hedge Fund Activity: Q2 2017 in Review

90 of the 4,011 institutional investors tracked by Wall St. Rank reported a position in BioSpecifics Technologies Corp. (BSTC) for Q2 2017, worth a combined $199M — down 22% from $255M a quarter earlier.

Buyers outnumbered sellers: 7 funds opened new BSTC positions and 6 closed out — a net gain of 1 holder — while 34 added to existing stakes and 34 trimmed.

The largest buyer was Stonepine Capital Management, opening a new position worth an estimated $3.14M. The largest seller was Numeric Investors, cutting an estimated $2.74M.

  • 90 institutional investors held BioSpecifics Technologies Corp. (BSTC) as of Q2 2017, up from 89 in Q1 2017.
  • Funds reported $199M of BioSpecifics Technologies Corp. stock for Q2 2017, down 22% quarter-over-quarter.
  • 7 funds opened new BioSpecifics Technologies Corp. positions in Q2 2017 and 6 closed out, a net change of +1 holder.
  • The largest BioSpecifics Technologies Corp. buyer in Q2 2017 was Stonepine Capital Management, an estimated $3.14M added.
  • The largest BioSpecifics Technologies Corp. seller in Q2 2017 was Numeric Investors, an estimated $2.74M sold.

Based on aggregated 13F filings for Q2 2017.